New Gene Therapy Trial Shows Promise for SCD Patients in Africa
A landmark clinical trial across three West African countries is showing early positive results in reducing painful crises for sickle cell disease patients.
Groundbreaking Research in West Africa
A landmark clinical trial across three West African countries is showing early positive results in reducing painful crises for sickle cell disease patients.
The trial, conducted in Nigeria, Ghana, and Senegal, involved 500 patients with sickle cell disease. After 12 months of treatment, researchers reported a 67% reduction in painful vaso-occlusive crises.
Key Findings
- 67% reduction in painful crises
- 80% of patients reported improved quality of life
- No severe adverse effects reported
- Treatment was well-tolerated across all age groups
"This is a breakthrough moment for sickle cell treatment in Africa," said Dr. Amara Okafor, lead researcher. "We are seeing results that could change the lives of millions of patients across the continent."
The research team is now preparing for a larger Phase 3 trial, with hopes of making the therapy available within the next 2-3 years.
Share this article
